EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
Related to GA Agenda item 9.4
The European Commission has recognised the criticisms made of the existing regulatory regime for clinical trial regulation in Europe and accordingly was developing its proposals for reform throughout 2011 and 2012.
In advance of its publication the 2012 EAHP General Assembly passed a statement on clinical trial regulation, setting out hospital pharmacist views on areas requiring attention. This focused on the need for greater transparency about how clinical trial results are published, efforts to be made to improve under-represented patient group participation (e.g. older people, children, females), and gave general support for suggestions of risk-adapted approaches to regulation (e.g. lower burden requirements for low intervention trials). More information here.
Following the passage of the new EAHP statement, the Commission published their proposals for reform of the Clinical Trials Directive in July 2012 (information here) and EAHP met with the Commission to discuss our views shortly thereafter (information here).
Beyond this, EAHP has been working with organisations with a common interest to present joint amendments and messages to the European Parliament. This includes partners in the European Public Health Alliance (EPHA) such as: Cancer Research UK, the European AIDS Treatment Group (EATG), the European Heart Network, AGE Platform Europe, and the European Hematology Association (EHA).
In November 2012 EAHP took part in a joint briefing supporting many aspects of the Commission's proposals but seeking greater clarity about how certain aspects (e.g. risk-proportionate measures) would operate in practice. Joint briefing here.
EAHP also helped to develop, and supported, an EPHA position paper on clinical trials, which reemphasised the need for efforts to improve patient group participation. Paper here.
Following this activity, at the end of January 2013 Glenis Wilmott MEP (UK, Socialist Group) published her draft report on behalf of the European Parliament's ENVI (health) Committee. The draft report is available in different languages here. Opinion reports were also published around the same time by the Civil Liberties Committee, the Industry and Research Committee, and the Internal Market Committee (IMCO).
Amendments of the Parliament have focused on the extent of trial result transparency measures (in particular as to whether all trial results should be reported in the form of clinical study reports) and the handling of personal data (e.g. for how long this should be held and when or if it should be destroyed).
In the meantime, a campaign called AllTrials, led by the Cochrane Collaboration, British Medical Journal and Sense about Science, has been leading an collaborative advocacy exercise to ensure all trials are fully reported, not just successful trials. The April Board Meeting of EAHP agreed to join the organisations supporting the campaign. See supporting organisations here.
Separately to the above, EAHP has attended many meetings of the European Medicines Agency to give health professional input to the development of their clinical trials database (EUDRACT) and nominated representatives to its 5 working groups investigating trial data access issues. More information here.
The European Parliament's ENVI Committee is scheduled to vote on the content of its final report on the Commission proposals on clinical trial regulation at the end of May 2013. After this vote the subject file will enter a process of "trilogue" discussion between the European Parliament, the European Commission and Council of Ministers (representing national Governments). The subject file is due to be closed by a final vote of the whole European Parliament in October 2013.
EAHP will continue to work with partner organisations (e.g. through EPHA, Alltrials and others) in scrutinising and giving advice and suggestions to Parliament, the Commission and Governments in relation to proposed amendments to regulation.
Otherwise, the reforms to the Directive should represent improvements to the current regulatory regime, with greater public and professional access to clinical trial data, separation of regulatory burden for high and low intervention trials, and the possibility of co-sponsorship of trials.
Activity throughout 2012 has also helped to raise the profile of hospital pharmacists in relation to clinical trial activity with relevant European audiences, and assisted in building alliances with stakeholder organisations with similar interests. For example, Members of the European Parliament proactively saught the opinion of EAHP on proposed and potential amendments.
EAHP will continue to input to European Medicines Agency activity in relation to clinical trials, in particular the operation and accessibility of the EUDRACT database.
*EAHP would like to thank Velina Dimitrova, Hana Bakhouche, Sebastião Ferreira da Silva, and Carla Sousa, for their help and assistance in representing the hospital pharmacist perspective to the EMA trial data working groups.
